MedCity News is reporting that SPR Therapeutics of Cleveland, Ohio is close to receiving FDA regulatory approval for its SMARTPATCH Peripheral Nerve Stimulation System aimed at treating shoulder pain in patients post stroke. The device utilizes percutaneous leads to stimulate muscle activity and in turn reduce pain. (Read More)
Infecting a virus on your computer is a surefire way to make it go crazy, but what happens if you afflict it with schizophrenia? Computer networks that can’t forget fast enough can show symptoms of a kind of virtual schizophrenia, giving researchers further clues to the inner workings of schizophrenic brains, researchers at The University of Texas at Austin and Yale University have found. (Read More)
Research to restore sight to the clinically blind has reached a critical stage, with testing underway of the prototype microchips that will power the bionic eye. (Read More)
Medtronic, Inc. (NYSE: MDT) announced that data from a multicenter, prospective, randomized, blinded, feasibility trial published today show promise for occipital nerve stimulation (ONS) for treating medically refractory chronic migraines and support the need for further controlled study of the treatment. (Read More)
Fuzzy and green with purple bows on her head, Charlie may look like a creature you’d find palling around with the Muppets, but she’s actually a robot specially designed by a University of South Carolina doctoral student to help children with autism. (Read More)
Boston Scientific has received the CE Mark and is launching in Europe the Vercise Deep Brain Stimulation (DBS) System for patient’s with Parkinson’s. The Vercise is unique in that it allows physicians to selectively control the electric current delivered through each individual electrode. (Read More)
Neuros Medical, Inc., a neuromodulation company based in Cleveland, OH, has received Investigational Device Exemption (IDE) approval from the FDA for its high frequency Electrical Nerve Block technology for use in acute treatment of residual limb pain in amputees. (Read More)
The ReNaChip project aims to develop a biomimetic, biohybrid model that can demonstrate the recovery of a learning response that is lost with age. The project supports the development of a number of component technologies that will be integrated and clinically implemented. (Read More)
Data presented from a pivotal, phase III randomized clinical trial for patients with recurrent glioblastoma tumors suggest that Tumor Treating Fields (TTF) therapy may increase median survival time and improve quality of life scores compared to best standard of care chemotherapy. Professor Zvi Ram, chairman of the Department of Neurosurgery at Tel-Aviv Sourasky Medical Center, presented the data at the Society for Neuro-Oncology (SNO) Annual Scientific Meeting. (Read More)
Migraine is a neurological disorder characterized by a number of specific symptoms that can last for hours or days at a time. The severity of each migraine attack can vary widely, with typical symptoms ranging from sensitivity to light, noise and motion to nausea and vomiting in addition to headache. In general, chronic migraine sufferers have progressed to the level where they have migraine or migraine-like symptoms on more days than they are migraine free. St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced it has received European CE Mark approval of its Eon™ family of neurostimulators for patients with intractable chronic migraine.
